Skip to content

HPV/Genital Warts Health Center

Experimental Vaccine Targets Genital Cancer

Study Shows Vaccine Is Effective in Women Who Are Already Infected With HPV
Font Size
A
A
A
By
WebMD Health News
Reviewed by Louise Chang, MD

Nov. 4, 2009 -- An experimental human papilloma virus (HPV) vaccine shows early promise for preventing genital cancer in high-risk women who are already infected with the virus.

Infected women with precancerous lesions caused by HPV showed regression of the lesions after being given the experimental vaccine in a study reported today by researchers from the Netherlands in the New England Journal of Medicine.

The study included just 20 women. Researchers tell WebMD they are working to improve the vaccine before moving on to larger trials.

But the findings suggest it may be possible to prevent genital cancers by vaccinating HPV-infected women at high risk for developing the disease. "We were able to successfully treat women with these HPV-caused lesions," study researcher Gemma G. Kenter, MD, PhD, says. "And we were able to show lesion regression over a two-year period."

The two commercially available HPV vaccines, Gardasil and Cervarix, are designed to prevent initial infection with specific strains of the sexually transmitted HPV virus that cause most cervical cancers.

Because of this, they are most effective when given before the onset of sexual activity. The CDC recommends that the vaccine be given to girls between the ages of 11 and 12 and that it not be given to women older than 26.

Like the commercially available vaccines, the experimental vaccine targets the HPV 16 virus, which is a leading cause of cervical cancer and other genital cancers.

Women at High Risk for Cancer

The women in the study all had the precancerous genital lesions, known as vulvar intraepithelial neoplasia (VIN), which put them at high risk for developing cancer of the vulva. The lesions were also advanced enough to require treatment.

The women were vaccinated up to four times with the experimental vaccine.

Three months after treatment, 12 of the 20 women had clinical responses and reported relief of symptoms such as persistent itching. Five of the women had complete regression of their lesions and evidence of HPV-16 infection was no longer detectable in four of them.

Two years after treatment, about half the women no longer had the lesions and had no symptoms.

Today on WebMD

HPV Vaccine Future
Article
STD Overview
Slideshow
 
STD Facts Quiz
Quiz
Syringes and graph illustration
Tool
 
Sex Drive Killers
Slideshow
Genital Herpes Risks Quiz
Quiz
 
Young couple holding hands
Quiz
Herpes Vaccine Study
Video
 
Condom Quiz
Quiz
HPV Symptoms Tests
Article
 
Get The STD Picture
Feature
cancer cell
Slideshow
 

WebMD Special Sections